pharma · Duchenne Muscular Dystrophy · Gastroparesis · PCSA
Processa Pharmaceuticals
Processa Pharmaceuticals clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Hanover, USA
- Employees
- 16
- Programs
- 8
- Drugs
- 2
- Patents
- 0
Processa Pharmaceuticals projects
8 ClinicalTrials.gov programs sponsored by Processa Pharmaceuticals.
Processa Pharmaceuticals has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
HT-100
Processa Pharmaceuticals
Duchenne Muscular Dystrophy
2 trials -
PCS12852
Processa Pharmaceuticals
Gastroparesis
1 trial -
PCS499
Processa Pharmaceuticals
Necrobiosis Lipoidica
2 trials -
PCS6422 and capecitabine
Processa Pharmaceuticals
Breast Cancer
1 trial -
RX-3117
Processa Pharmaceuticals
Solid Tumor
1 trial -
RX-3117
Processa Pharmaceuticals
Metastatic Pancreatic Cancer
1 trial -
PCS499
Processa Pharmaceuticals
Healthy
1 trial -
PCS6422 and capecitabine
Processa Pharmaceuticals
Advanced Cancer
1 trial
Frequently asked questions
How many clinical projects does Processa Pharmaceuticals have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.